well as genetic factors 5) are associated with high on-treatment platelet reactivity (OPR). Moreover it has been reported that the use of various platelet function assays to identify patients with high OPR could predict the risk of thrombotic complications 1-3, 6, 7) . The VerifyNow-Aspirin and VerifyNow-P2Y12 assays are point-of-care tests (POCT) that measure residual platelet reactivity via the cyclooxygenase-1 and P2Y12 purinergic receptor pathways, respectively, and can detect the efficacy of aspirin and clopidogrel to inhibit platelet activity after drug administration at the bedside 8) . Although some reports have explained the relationship of either assay alone with clinical events 1, 2, 7, 9, 10) , data are limited regarding the efficacy of employing two types of POCT together to predict events 11, 12) .
Aim
In this post-hoc analysis of the CILON-T randomized trial 13, 14) , we analyzed whether a combination of the two types of POCT may have added benefit in predicting the future clinical outcome post-PCI compared with either assay alone.
Methods

Study Objectives, Hypothesis and Design
The CILON-T trial was a prospective, multicenter, randomized trial that recruited 960 patients treated with drug-eluting stents (DES) for coronary heart disease (CHD). The primary objective of this study was to compare whether 6 months' triple antiplatelet therapy (TAT, aspirin 100 mg clopidogrel 75 mg cilostazol 200 mg) is superior to dual antiplatelet therapy (DAT, aspirin 100 mg clopidogrel 75 mg) in reducing major adverse cardio/cerebrovascular events (MACCE) at 6 months post-PCI in those with documented CHD. The main results of this study have been published previously 14) . Patients with a variety of CHD were included and were randomized 1:1 to take either DAT (aspirin 100 mg daily and clopidogrel 75 mg daily) or TAT (cilostazol 200 mg daily added to DAT) for 6 months and also, stratified to the type of statin (Cytochrome P450 3A4 (CYP3A4)-metabolized vs. non-CYP3A4 metabolized). All coronary lesions except ISR lesions were included. Patients were recommended to measure the platelet reactivity using VerifyNow Aspirin and VerifyNow P2Y12 before discharge. The protocol of the trial has been registered at www.clinicaltrials.gov (NCT00776828) and the detailed protocol has been published elsewhere 13) .
PCI and Anti-Platelet Agents
All patients received 300 mg aspirin and 300-600 mg clopidogrel loading before the procedure unless the patient had been taking these medications for at least 1 week before the procedure. If randomized to the TAT group, a loading dose of cilostazol 200 mg was given immediately before the procedure. Unfractionated heparin was given according to the hospital's protocol with a target range of ACT 250-300 msec. PCI was performed according to the standard technique and the use of glycoprotein b/ a inhibitors was the surgeon's decision.
After enrollment and the index PCI procedure, clinical follow-up was planned at 1, 3, 6 months and all patients were recommended to have follow-up coronary angiography at 6 months. During the 6 months' follow-up, all patients were instructed to take aspirin, clopidogrel (and cilostazol if randomized to the TAT group) daily. The investigators followed the patients regularly, either by routine office visits or by telephone as necessary.
Measurement of Platelet Reactivity
On-treatment platelet reactivity (OPR) of the patients was assessed using VerifyNow Aspirin and P2Y12 assays (Accumetrics, San Diego, CA, USA). In brief, venous blood samples anticoagulated with sodium citrate 0.109 mol/L (ratio 9:1) were taken from each patient just before discharge while on a stable maintenance dose of 100 mg aspirin, 75 mg clopidogrel 200 mg cilostazol. In patients that used an intravenous glycoprotein b/ a inhibitor, the time gap between the PCI and the measurement of platelet reactivity was at least 5 days.
The VerifyNow system is a turbidimetry-based optical detection device that measures platelet aggregation in a column that contains fibrinogen-coated beads. VerifyNow Aspirin uses arachidonic acid as a specific agonist for platelet aggregation, whereas VerifyNow P2Y12 uses adenosine diphosphate. The results of the assay are reported as aspirin reaction units (ARU) and P2Y12 reaction units (PRU) 1) , and the variability of the tests has been reported to be 10% 15, 16) and 7.5% at our institutions.
Data Collection and Clinical Follow-Up of the Patients
After enrollment and the index PCI procedure, clinical follow-up was planned at 1, 3 and 6 months. The endpoints of the current study were as follows. 1) Cardiac death, which was defined as death unless there was an explicit cause of noncardiac cause of death 2) Nonfatal myocardial infarction (MI), defined as a significant increase of cardiac enzyme of at least three times the upper normal limits with either typical ischemic symptoms or typical ECG change compatible with myocardial ischemia 3) Ischemic stroke, defined as a neurologic deficit lasting for at least 24 hours with definite evidence of a nonhemorrhagic intracranial lesion on intracranial imaging that is compatible with the neurologic deficit.
Statistical Analysis
Continuous variables are presented as the mean standard deviation and categorical variables as frequencies in percentages. Differences between groups were compared with either the unpaired t -test, 2 -test or Fisher's exact test as appropriate.
The cumulative incidence rate of each group was constructed using the Kaplan-Meier method and the log-rank test was used to assess the statistical significance between the groups. Univariate and multivariate analysis was performed using the Cox proportional hazard model to identify risk factors of thrombotic events. Also, the receiver-operating characteristic (ROC) curve was used to demonstrate the optimal value of ARU and PRU to predict thrombotic events, respectively, and also to determine the predictability of cardiovascular risk factors, risk factors highest tertile of PRU, risk factors highest tertile of the sum of tertiles of ARU and PRU, respectively. The cardiovascular risk factors used in this analysis included classical All statistical analysis was performed with SPSS 17.0 (SPSS Inc., Chicago, IL, USA) and p 0.05 was considered significant.
Results
From 915 patients in the CILON-T trial, 199 patients did not agree to measurement of OPR, so 716 patients were enrolled in this substudy of CILON-T. The results of both assays were plotted in a 3-by-3 factorial manner and patients were divided into tertiles according to ARU and PRU results, respectively (Fig. 1A) . Independently, ARU tertiles were not able to discriminate patients with future thrombotic events, a composite of cardiac death, nonfatal MI and ischemic stroke (p 0.197 for log-rank test) (Fig. 1B) . Tertiles of PRU were independently only marginally effective in discriminating events (p 0.058 for log-rank test) (Fig. 1C) .
To test whether the combination of ARU and PRU values would be better to predict future thrombotic events, the patients were divided into three groups according to the sum of the tertile of the ARU and PRU levels. Scores were calculated by adding the (A) The patients were divided according to the tertiles of ARU and PRU, respectively. Group 1 was defined as patients with 1st ARU tertile and 1st PRU tertile, 2nd ARU tertile and 1st PRU tertile or 1st ARU tertile and 2nd PRU tertile (area not shaded). Group 3 was defined as patients with 2nd ARU tertile and 3rd PRU tertile, 3rd ARU tertile and 2nd PRU tertile or 3rd ARU tertile and 3rd PRU tertile (area shaded in light gray). The remaining patients were classified as group 2 (area shaded in blue). (B) Significant difference in the cumulative incidence of thrombotic events upto 6 months between groups 1, 2 and 3. (C) Significant difference in the cumulative incidence of thrombotic events upto 1 month between groups 1, 2 and 3. (D) Marginal difference in the cumulative incidence of ischemic stroke upto 6 months between groups 1, 2 and 3.
A B C D score of each axis (ARU by tertile PRU by tertile). Group 1 was defined as the group of patients with total score 0 or 1, group 2 as total score 2 and group 3 as total score 3 or 4 ( Fig. 2A) . Comparison of the baseline clinical, medical and angiographical characteristics of the three groups is summarized in Table 1 and the incidence of each endpoint is summarized in Table 2 . Patients were slightly older, shorter and the proportion of females higher in the group with the highest combined platelet reactivity (group 3) than in the other two groups. In contrast to the lack of significance of PRU and ARU tertiles in predicting thrombotic events independently (Fig. 1B & C) , the combination of PRU and ARU values was a significant predictor of future thrombotic events (Fig. 2B) , which was driven by the significant increase in early throm- Fig. 2C ) and ischemic stroke ( Table 2, Fig. 2D ) in group 3. Also, it was notable that only one thrombotic event occurred in group 1 and 2, respectively, in contrast to the nine thrombotic events in observed in group 3 (the group with the worst PRU and ARU tertiles). In addition, three of the MI events were attributed to stent thrombosis and these three events occurred exclusively in group 3, whereas one MI event in group 1 occurred in the nonintervened vessel. There was one TIMI major bleeding in one patient in group 3 and one minor bleeding in one patient in group 2. Multivariate Cox's regression analysis using classical clinical risk factors and either the highest tertile of PRU or highest tertile of the sum of ARU and PRU demonstrated that the highest combined ARU and PRU tertile was the only significant predictor of future thrombotic events (HR 6.34, 95% confidence interval 1.32-30.47, p 0.021). Even after adding the angiographical risk factors listed in Table 1 , only the highest tertile of the sum of ARU and PRU remained a significant predictor of future thrombotic events (HR 6.75, 95% confidence interval 1.12-40.56, p 0.037) but the highest tertile of PRU was insignificant (HR 4.08, 95% confidence interval 0.80-20.75, p 0.092). Moreover, the addition of the highest combined ARU and PRU tertiles on top of classical cardiovascular risk factors (age, sex, diabetes, hypertension, hyperlipid- emia, current smoking) improved the ability of the ROC curve to predict 6-month thrombotic events as compared with only classical risk factors or classical risk factors highest tertile of PRU tertile (Fig. 3) .
Discussion
In this POCT sub-analysis of the CILON-T prospective randomized trial, we found that the combination of two POCT results can predict future thrombotic events after DES implantation more effectively than either test alone. Although numerous studies have separately shown that aspirin 9) or clopidogrel non/hyporesponsiveness 1, 2, 7) can be a predictor of future cardiac events, studies evaluating the usefulness of combining the two POCT results are limited.
Anti-Platelet Resistance, its Clinical Implication and Shortcomings
There are several methods that assess aspirin and clopidogrel responses, from the widely-accepted gold standard light transmission aggregometry to simple POCTs, such as the VerifyNow rapid platelet function assay 8, 17) that was employed in our trial. However, regardless of the method used to assess anti-platelet agent resistance, it is widely accepted that aspirin or clopidogrel resistance is correlated with adverse clinical outcomes 1, 2, 6, 7, 9, 11) . The VerifyNow Aspirin and P2Y12 assays were suggested to be associated with adverse thrombotic events after PCI using a cutoff value of 550 ARU and 235-240 PRU in Caucasians 1, 2, 7, 9, 18) . These cut-off values were shown to have a fair sensitivity and specificity of approximately 60-70% with an excellent negative predictive value.
According to the data in this study, the optimal ARU and PRU cut-off values were 473.5 and 252.5 14) , respectively; however, the predictability of ARU was not significant (p 0.213, AUC 0.615, 95% CI 0.440~0.790) and PRU was marginally significant (p 0.043, AUC 0.670, 95% CI 0.579~0.762). The difference in these cut-off values may be due to racial differences and also, differences in the risk factors, the influence of which has all been demonstrated in previous papers 4, 19) .
The Pitfall of Assessing Platelet Responsiveness with Only One Agonist
Despite the predictive value of ARU and PRU, albeit with different cut-off values and predictabilities, assessing platelet resistance with only one agonist, either arachidonic acid (ARU) or ADP (PRU) alone, fails to identify the most at-risk population of developing thrombotic events. In light of this, earlier reports by Gori 11) and Lev 12) demonstrated a unique population of patients with dual nonresponsiveness to aspirin and clopidogrel. These patients, who comprised 5-10% of the whole study population 11, 12) , were at higher risk of developing thrombotic cardiac events post-PCI than patients with only one antiplatelet agent resistance. Specifically, compared to patients responding to both antiplatelet agents, the risk of cardiac death and stent thrombosis was approximately 3-and 5-fold higher in single agent (clopidogrel)-resistant and dual agent-resistant patients, respectively 11) . Although this may not be surprising, considering the clinical impact of either aspirin or clopidogrel non/ hyporesponsiveness alone, it demonstrates an important concept that platelet function should be assessed from various aspects, which has also been suggested by others 8) . In particular, considering that aspirin is the mainstay, and sometimes the only anti-platelet agent after six months -one year of PCI 20) , the importance of aspirin resistance has been rather neglected compared to clopidogrel resistance.
One of our objectives in this substudy of CILON-T trial was to observe the platelet responsiveness from various aspects by classifying the responsiveness of platelets into both arachidonic acid-dependent and P2Y12 receptor-dependent variables. This effort has suggested the possible superiority of combining both variables over either one alone in distinguishing a group of patients at highest risk of future thrombosis after PCI.
Platelet Responsiveness as a Possible Predictor of Early Events and Cerebrovascular Events
More detailed analysis of our data suggested that the group with the highest combined platelet reactivity was most likely to experience early cardiac events ( 30 days) and also, ischemic stroke post-PCI. Although, it is controversial whether high OPR is a significant predictor of early or late stent thrombosis (ST), several studies have pointed to the evidence that residual platelet aggregation is a predictor of shortterm and partially, early ST [21] [22] [23] . This may be clinically relevant because endothelialization progresses over time and it is in the early post-stenting period that most of the stent strut is exposed to blood components. Also, taking into account that a hypersensitivity reaction to a drug or polymer and delayed healing is a major factor of late (LST) or very late ST (VLST) [24] [25] [26] [27] , several factors other than the degree of OPR might be related to LST/VLST. Also, there have been only a few data on whether platelet function tests, much less POCTs, would be useful to predict ischemic cerebrovascular events. One meta-analysis has shown that aspirin resistance was associated with a 3.78-fold increase in a new cerebral event 28) . There are no reliable data on the predictability of clopidogrel resistance in stroke only, although ample evidence exists on its predictive efficacy on overall cardiovascular outcomes; therefore, our novel piece of data suggesting the efficacy of on-treatment platelet reactivity in ischemic stroke remains to be confirmed in a larger trial.
Limitations
Our results have some inherent limitations. First of all, this study is a post-hoc analysis of a randomized trial and was not powered to demonstrate the difference in MACCE or thrombotic events according to the ARU and PRU values; therefore, our analysis is at best hypothesis-generating and should be taken with caution as to the clinical relevance of the effect of combining two POCTs. Second, some patients with thrombotic events, especially three with cardiac death, could not be included in the analysis because they had not agreed to POCT, and thus the ARU and PRU values were not available for these patients at discharge.
Third, only a minority of the patients in the study population reached the primary endpoint, which is in contrast to previous reports where dual nonresponders showed 13% cardiac death and stent thrombosis; however, it is very unlikely that nearly all of the patients with events (over 80% in group 3) would be in only one group just by chance. In addition, the racial difference, which includes substantial differences in the genetic variation of CYP enzymes, may have influenced the primary outcome. For example, the difference in the incidence of stent thrombosis varies widely between Caucasians and Asians 29, 30) , which may be a consequence of this genetic variation.
Conclusion
In this sub-analysis of the CILON-T trial, combining the results of VerifyNow Aspirin and P2Y12 simultaneously, may play a significant role in discriminating patients at high risk of future thrombotic events after PCI. Our analysis suggests the prognostic value of using both POCT together.
